Dr Reddy’s Laboratories is entering the hormone replacement therapy (HRT) segment in India by acquiring trademarks for Progynova and Cyclo-Progynova from Mercury Pharma Group for $32.15 million. This strategic move aims to strengthen Dr Reddy’s gynecology portfolio and expand its presence in the HRT market, which addresses symptoms related to estrogen deficiency and menopause. The acquired brands generated sales of Rs 100 crore as per IQVIA MAT December 2025 data.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Dr Reddy's acquires India trademarks for 2 HRT drugs from UK's Mercury Pharma for $32 million
Dr Reddy’s Laboratories is entering the hormone replacement therapy (HRT) segment in India by acquiring trademarks for Progynova and Cyclo-Progynova from Mercury Pharma Group for $32.15 million. This strategic move aims to strengthen Dr Reddy’s gynecology portfolio and expand its presence in the HRT market, which addresses symptoms related to estrogen deficiency and menopause. The acquired brands generated sales of Rs 100 crore as per IQVIA MAT December 2025 data.